Article (Scientific journals)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density.
McClung, Michael R.; Grauer, Andreas; Boonen, Steven et al.
2014In New England Journal of Medicine, 370, p. 412-420
Peer Reviewed verified by ORBi
 

Files


Full Text
Romosozumab in postmenopausal women with low bone mineral density.pdf
Publisher postprint (546.24 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Background Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. Methods In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator - oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 mug daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. Results All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. Conclusions In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532 .).
Disciplines :
General & internal medicine
Author, co-author :
McClung, Michael R.
Grauer, Andreas
Boonen, Steven
Bolognese, Michael A.
Brown, Jacques P.
Diez-Perez, Adolfo
Langdahl, Bente L.
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Zanchetta, Jose R.
Wasserman, Scott M.
Katz, Leonid
Maddox, Judy
Yang, Yu-Ching
Libanati, Cesar
Bone, Henry G.
More authors (5 more) Less
Language :
English
Title :
Romosozumab in Postmenopausal Women with Low Bone Mineral Density.
Publication date :
2014
Journal title :
New England Journal of Medicine
ISSN :
0028-4793
eISSN :
1533-4406
Publisher :
Massachusetts Medical Society, United States - Massachusetts
Volume :
370
Pages :
412-420
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 09 January 2014

Statistics


Number of views
129 (11 by ULiège)
Number of downloads
2 (1 by ULiège)

Scopus citations®
 
891
Scopus citations®
without self-citations
826
OpenCitations
 
796

Bibliography


Similar publications



Contact ORBi